Lapaquistat acetate (also known as TAK-475) is a squalene synthase inhibitor primarily investigated for its potential in managing cholesterol levels. It works by inhibiting the enzyme squalene synthase, a key step in cholesterol synthesis, making it a candidate for treating hypercholesterolemia. Research focused on its ability to lower LDL cholesterol, often referred to as "bad" cholesterol, which is a significant risk factor for cardiovascular diseases. Clinical studies explored its efficacy and safety as a therapeutic agent, particularly for patients who do not respond adequately to traditional statin treatments. However, development was discontinued by Bayer in 2007 due to concerns over elevated liver enzymes and potential hepatotoxicity. It remains available for research purposes as an alternative or adjunct therapy model for studying cholesterol control and cardiovascular health outcomes.